Healthcare / Pharmaceutical RetailersShanghai
$10.92
+0.35 (+3.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $44.6M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
32.1x
↑EV/EBITDA
15.5x
↑ROE
5.0%
↑Gross Margin
16.0%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.1%
FCF CAGR
-15.5%
FCF margin
3.4%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.13B · net income $57.7M · FCF $73.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.13B | $2.13B | $1.92B | $1.82B | $2.66B |
| Net Income | $57.7M | $57.7M | $163.1M | $89.3M | $143.6M |
| EBITDA | $150.2M | $150.2M | $288.0M | $179.1M | $253.0M |
| EPS | 0.26 | 0.26 | 0.73 | 0.40 | 0.64 |
| Gross Margin | 16.0% | 16.0% | 16.6% | 19.1% | 20.5% |
| Operating Margin | 0.4% | 0.4% | -0.4% | 1.2% | 8.7% |
| Net Margin | 2.7% | 2.7% | 8.5% | 4.9% | 5.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.24 | 0.26 | 0.48 |
| Current Ratio | 1.69 | 1.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $73.0M | $73.0M | $-2.9M | $44.6M | $120.9M |
| Returns | |||||
| ROE | 5.0% | 5.0% | 14.4% | 8.9% | 15.1% |
| Valuation | |||||
| P/E | 32.12 | 32.12 | 16.52 | 29.97 | 17.27 |
| EV/EBITDA | 15.47 | 15.47 | 8.79 | 14.17 | 9.61 |
| P/B | 2.09 | 2.09 | 2.37 | 2.67 | 2.60 |
| Growth & Yield | |||||
| Revenue Growth | 11.2% | 11.2% | 5.3% | -31.5% | — |
| EPS Growth | -64.4% | -64.4% | 82.5% | -37.5% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
55.0%
EPS terminal req.
$0.97
Spread vs growth
-119.4%
5Y implied EPS CAGR
35.2%
EPS terminal req.
$1.17
Spread vs growth
-99.5%
10Y implied EPS CAGR
21.9%
EPS terminal req.
$1.89
Spread vs growth
-86.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.1%
Start / end P/E
16.8x → 42.0x
EPS bridge
0.73 → 0.26
Residual
-96.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.